Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

ophosphamide and rituximab; or BR = bendamustine and rituximab) in subjects with CLL or SLL lymphoma. This trial is active in several US sites and completed enrollment with 30 of 30 patients to the BR cohort. We anticipate providing an update of safety results from this study concurrent with releases that are planned for calendar Q4 2011.
  • PCYC-1109:  A Phase IB/II study of PCI-32765 in combination with ofatumumab in subjects with relapsed or refractory CLL or SLL is ongoing and enrolled 33 patients as of the end of August, 2011. We anticipate providing an update on safety results from this study concurrent with releases that are planned for calendar Q4 2011.

  • Ongoing pre-clinical studies, both internally as well as through external collaborations, have suggested a potentially vital role for Btk in both malignant plasma cells and osteoclasts, which are involved in the bone complications of this disease. Therefore, we believe that Btk represents a viable therapeutic target in Multiple Myeloma and we are on track to initiate a Phase II trial of PCI-32765 in this disease in Q1 of calendar 2012.

  • Factor VIIa InhibitorA multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy is currently ongoing.  The Phase II portion of the study is enrolling and patients are being randomized to receive either gemcitabine alone or gemcitabine plus PCI-27483. The objectives is to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Currently we have enrolled 23 patients in the Phase II portion of this trial and we expect to complete enrollment of our planned 40 patients by Q1 of calendar 2012.

    Histone Deacetylase (HDAC) Inhibito
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
    2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
    3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
    4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
    5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
    6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
    7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
    8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
    9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
    10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
    11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)...  Aethlon Medical, Inc. (OTCQB:AEMD), announced today that it ... $3.3 million at a price of $0.30 per unit. ... investor. Each unit consists of one common share and ... Each whole warrant entitles the holder to acquire one ... period of five years from closing.  ...
    (Date:11/26/2014)... Calif. , Nov. 26, 2014  Genomic Health, ... Kim Popovits , Chairman, Chief Executive Officer and President, ... Jaffray Healthcare Conference at The New York Palace Hotel ... December 3 at 11:30 am Eastern Time (ET). ... of the conference call, go to the  Investor Relations ...
    (Date:11/26/2014)... , Nov. 26, 2014  Avanir Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has ... Drug Application (NDA) for AVP-825. AVP-825 is an ... powder delivered intranasally utilizing a novel Breath Powered ... Response letter, and consistent with the preliminary feedback ...
    Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
    (Date:11/28/2014)... NEW ALBANY, IN (PRWEB) November 28, 2014 ... of Americans were already preparing for the Christmas shopping season. ... the best deals on Black Friday, the biggest retail shopping ... the latest gadget or electronic device, New Albany dentist ... gift options that can improve oral health and literally brighten ...
    (Date:11/28/2014)... (PRWEB) November 28, 2014 Based in ... organization focused on delivering exemplary solutions to the income ... ancillary benefits. In an effort to extend its reach ... and asset protection, Secura Consultants has brought aboard financial ... , “I am a big believer in specialization. When ...
    (Date:11/28/2014)... 28, 2014 Top10inaction.com, a popular product ... Best Styling Tools For Hair in 2014 at ... such as T3 Featherweight 2 Hair Dryer, ghd Eclipse ... listed. , With the significant increase of awareness on ... but also home-used hair styling tools become necessities in ...
    (Date:11/27/2014)... Recently, iFitDress.com, a reliable company of women’s special occasion ... of black cocktail dresses . The new models ... models are priced under $50. All customers who purchase ... a low shipping fee before Dec. 30, 2014. , ... The business has promised to offer only high quality ...
    (Date:11/27/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Bronchoscopes manufacturers and is a valuable source of ... the industry. , Firstly, the report provides a basic ... manufacturing technology. Then, the report explores the international and ...
    Breaking Medicine News(10 mins):Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 3Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 4Health News:Matt Lee, CLU, ChFC Joins Secura Consultants as New Brokerage Consultant 2Health News:T3 Featherweight 2 Hair Dryer Is Named As Best Hair Styling Tool 2Health News:Beautiful Black Cocktail Dresses Offered by Top Dress Supplier iFitDress.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3
    ... ... month offers a potential boon to the diagnostic lab industry in the form of new ... said lab industry expert Dennis Weissman at a Slone Partners teleconference on the new law ... Miami, FL ...
    ... ... can now benefit from having critical documents e-Notarized by David Walsh, Solicitor and Notary ... Portsmouth, ... the longest established Certification Authorities (CA) and specialists in digital certificate security, has today ...
    ... ... Myeexpert in partnership with Strategic Insight Publishing, took a step further with ... Healthy Living and Relationships. , ... (PRWEB) May 4, 2010 -- Quoting verses from the book, the Founder and CEO of ...
    ... ... LLP have again been named as Ohio Super Lawyers®. This honor, by the much respected ... accomplished medical malpractice attorneys. Congratulations! , ... Cleveland, OH (PRWEB) May 4, 2010 -- Spangenberg lawyers were again honored this ...
    ... ... shown that the NeverWet Clear-n-Clean Plunger repels contaminated toilet water, keeping this bathroom plunger ... ... of consumer products created with their patent-pending Nanotech coating that repels water. Its first ...
    ... As ... seekers to explore the water sector to discover careers that are both central to public ... ... Week continues, the American Water Works Association (AWWA) is urging students and job ...
    Cached Medicine News:Health News:Lab Industry Likely to Benefit from Expanded Preventive Testing Under New Health Care Law 2Health News:Lab Industry Likely to Benefit from Expanded Preventive Testing Under New Health Care Law 3Health News:GlobalSign Announces First Successful E-Notarization in Ireland 2Health News:GlobalSign Announces First Successful E-Notarization in Ireland 3Health News:GlobalSign Announces First Successful E-Notarization in Ireland 4Health News:“You Are Very Pretty”, Says Myeexpert As It Releases A Book, Poetic Expressions, Dedicated To The Beauty of Women. 2Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers on 2010 List 2Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers on 2010 List 3Health News:Ross Nanotechnology Corporation Introduces the NeverWet™ Coating on its First Consumer Product – The Clear-n-Clean Plunger 2Health News:During Drinking Water Week 2010, Water Sector Urges Students, Job Seekers to Work for Water 2
    Transcranial vascular DWL doppler....
    The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
    Transcranial vascular DWL doppler....
    Transcranial vascular DWL doppler....
    Medicine Products: